Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19.CAR-multiVST for CD19+ Malignancies Post-HSCT
NCT03768310Phase 1Withdrawn
- Sponsor
- Baylor College of Medicine
- Start
- Jun 2022
- Primary completion
- Aug 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD19.CAR-VSTs in non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Dose-Limiting Toxicities at 6 weeks. Planned start Jun 2022; status: withdrawn.
02
Drugs
CD19.CAR-VSTs
03
Conditions
non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03768310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03768310.